Patents Assigned to QBIOTICS PTY LTD
  • Publication number: 20220313648
    Abstract: The present invention relates to methods of dispersing biofilms comprising Gram-negative bacteria, the methods comprising exposing the biofilm to an epoxytiglienone compound or a salt thereof. Methods of treating infections comprising the localised administration, for example, topically or by injection, of an epoxytiglienone compound into or onto an established biofilm comprising Gram-negative bacteria to disrupt the structure of that biofilm and methods of preventing biofilms comprising Gram-negative bacteria forming or dispersing biofilms comprising Gram-negative biofilms that have formed on medical devices are also described.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: QBIOTICS PTY LTD
    Inventors: David William THOMAS, Paul Warren REDDELL, Glen Mathew BOYLE, Jason Kingsley CULLEN, Victoria Anne GORDON, Katja Etel HILL, Lydia Charlotte POWELL, Manon F. PRITCHARD, Peter G. PARSONS
  • Publication number: 20220193023
    Abstract: The present invention relates to methods of treating tumours comprising the localised administration, for example, intratumourally or topically, of an epoxytiglienone compound (as a monotherapy) to cancerous tumours to generate a systemic anticancer C abscopal (anenestic) and/or bystander effect.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 23, 2022
    Applicant: QBIOTICS PTY LTD
    Inventors: Victoria Anne GORDON, Paul Warren REDDELL, Glen Mathew BOYLE, Jason Kingsley CULLEN, Peter Gordon PARSONS
  • Patent number: 11213506
    Abstract: The present invention relates to a combination therapy for tumours comprising the administration of an epoxytigliane compound and an immune checkpoint inhibitor. In particular embodiments, there is a method of treating a tumour and/or treating or preventing one or more bystander tumours with the therapy. Pharmaceutical compositions and kits containing epoxytigliane compounds and immune checkpoint inhibitors are also described.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: January 4, 2022
    Assignee: QBIOTICS PTY LTD
    Inventors: Paul Warren Reddell, Jason Kingsley Cullen, Glen Mathew Boyle, Peter Gordon Parsons, Victoria Anne Gordon
  • Patent number: 10980769
    Abstract: The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: April 20, 2021
    Assignee: QBIOTICS PTY LTD
    Inventors: Paul Warren Reddell, Victoria Anne Gordon
  • Patent number: 10822317
    Abstract: The present invention relates to epoxy-tigliane compounds and their use in promoting wound healing. In particular embodiments, the epoxy-tigliane compounds are epoxy-tigliaen-3-one compounds. Methods of inducing or promoting wound healing as well as methods of reducing scarring and improving cosmetic outcomes upon healing of a wound are described. Compounds and compositions for use in wound healing are also described.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: November 3, 2020
    Assignee: QBIOTICS PTY LTD
    Inventors: Paul Warren Reddell, Victoria Anne Gordon, Ryan Moseley, Robert Steadman, Rachael Louise Moses, Glen Mathew Boyle, Peter Gordon Parsons
  • Patent number: 10543188
    Abstract: The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: January 28, 2020
    Assignee: QBIOTICS PTY LTD
    Inventors: Paul Warren Reddell, Victoria Anne Gordon